151 related articles for article (PubMed ID: 32791733)
1. Concomitant fulvestrant with reirradiation for unresectable locoregional recurrent estrogen receptor positive (ER+) breast cancer: A case report and narrative review.
Ding J; Guo Y; Jiang X; Li K; Fu W; Cao Y
Medicine (Baltimore); 2020 Jul; 99(30):e21344. PubMed ID: 32791733
[TBL] [Abstract][Full Text] [Related]
2. Fulvestrant May Falsely Increase 17β-Estradiol Levels in Immunoassays: A Case Report of a 57-Year-Old Postmenopausal Patient With Recurrent Estrogen Receptor-Positive Breast Cancer.
Ding J; Cao Y; Guo Y
Front Oncol; 2022; 12():832763. PubMed ID: 35494071
[TBL] [Abstract][Full Text] [Related]
3. Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.
Xie Y; Li Y; Zhang Y; Zhang S; Li W; Guan X; Zhao Y; Gong C; Hu X; Zhang J; Cao E; Wang L; Ge R; Wang B
Clin Breast Cancer; 2019 Jun; 19(3):e452-e458. PubMed ID: 30846408
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of fulvestrant 500 mg in Chinese postmenopausal women with advanced/recurrent breast cancer and factors associated with prolonged time-to-treatment failure: A retrospective case series.
Huang J; Huang P; Shao XY; Sun Y; Lei L; Lou CJ; Ye WW; Chen JQ; Cao WM; Huang Y; Zheng YB; Wang XJ; Chen ZH
Medicine (Baltimore); 2020 Jul; 99(29):e20821. PubMed ID: 32702824
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer.
Robertson JFR; Jiang Z; Di Leo A; Ohno S; Pritchard KI; Ellis M; Bradbury I; Campbell C
Breast Cancer; 2019 Nov; 26(6):703-711. PubMed ID: 31079343
[TBL] [Abstract][Full Text] [Related]
7. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
[TBL] [Abstract][Full Text] [Related]
8. Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer.
Blancas I; Olier C; Conde V; Bayo JL; Herrero C; Zarcos-Pedrinaci I; Carabantes F; Baena-Cañada JM; Cruz J; Ruiz-Borrego M
Sci Rep; 2021 Feb; 11(1):4274. PubMed ID: 33608590
[TBL] [Abstract][Full Text] [Related]
9. Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.
Woodward WA; Barlow WE; Jagsi R; Buchholz TA; Shak S; Baehner F; Whelan TJ; Davidson NE; Ingle JN; King TA; Ravdin PM; Osborne CK; Tripathy D; Livingston RB; Gralow JR; Hortobagyi GN; Hayes DF; Albain KS
JAMA Oncol; 2020 Apr; 6(4):505-511. PubMed ID: 31917424
[TBL] [Abstract][Full Text] [Related]
10. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
Chia S; Gradishar W; Mauriac L; Bines J; Amant F; Federico M; Fein L; Romieu G; Buzdar A; Robertson JF; Brufsky A; Possinger K; Rennie P; Sapunar F; Lowe E; Piccart M
J Clin Oncol; 2008 Apr; 26(10):1664-70. PubMed ID: 18316794
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.
Bachelot T; McCool R; Duffy S; Glanville J; Varley D; Fleetwood K; Zhang J; Jerusalem G
Breast Cancer Res Treat; 2014 Jan; 143(1):125-33. PubMed ID: 24272078
[TBL] [Abstract][Full Text] [Related]
12. Reirradiation of recurrent breast cancer with and without concurrent chemotherapy.
Würschmidt F; Dahle J; Petersen C; Wenzel C; Kretschmer M; Bastian C
Radiat Oncol; 2008 Sep; 3():28. PubMed ID: 18801165
[TBL] [Abstract][Full Text] [Related]
13. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy can decrease locoregional recurrence and increase survival in mastectomy patients with T1 to T2 breast cancer and one to three positive nodes with negative estrogen receptor and positive lymphovascular invasion status.
Yang PS; Chen CM; Liu MC; Jian JM; Horng CF; Liu MJ; Yu BL; Lee MY; Chi CW
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):516-22. PubMed ID: 19577858
[TBL] [Abstract][Full Text] [Related]
15. Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer.
Ohno S
Clin Breast Cancer; 2016 Aug; 16(4):238-46. PubMed ID: 27151773
[TBL] [Abstract][Full Text] [Related]
16. Reirradiation and hyperthermia for irresectable locoregional recurrent breast cancer in previously irradiated area: Size matters.
Oldenborg S; Griesdoorn V; van Os R; Kusumanto YH; Oei BS; Venselaar JL; Zum Vörde Sive Vörding PJ; Heymans MW; Kolff MW; Rasch CR; Crezee H; van Tienhoven G
Radiother Oncol; 2015 Nov; 117(2):223-8. PubMed ID: 26542015
[TBL] [Abstract][Full Text] [Related]
17. Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real-world study for patients with hormone receptor-positive and HER2-negative advanced breast cancer.
Zhao Y; Li Y; Gong C; Xie Y; Zhang J; Wang L; Cao J; Tao Z; Wang B; Hu X
Cancer Med; 2020 Dec; 9(23):8821-8831. PubMed ID: 33022852
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive locoregional treatment and systemic therapy for postmastectomy isolated locoregional recurrence.
Kuo SH; Huang CS; Kuo WH; Cheng AL; Chang KJ; Chia-Hsien Cheng J
Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1456-64. PubMed ID: 18692329
[TBL] [Abstract][Full Text] [Related]
19. Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies.
Agrawal A; Robertson JF; Cheung KL; Gutteridge E; Ellis IO; Nicholson RI; Gee JM
Int J Cancer; 2016 Jan; 138(1):146-59. PubMed ID: 26178788
[TBL] [Abstract][Full Text] [Related]
20. Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy.
Heo MH; Kim HK; Lee H; Kim JY; Ahn JS; Im YH; Park YH
Korean J Intern Med; 2019 Sep; 34(5):1100-1106. PubMed ID: 29540055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
